Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.

Alkermes plc announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA's Center for Biologics Evaluation and Research, has sent reverberations throughout the ...

Neurogene Inc.’s NGNE share price has dipped by 18.34%, which has investors questioning if this is right time to buy.

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on ...

Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

Neurogene Inc. (NASDAQ:NGNE – Get Free Report) has received a consensus rating of “Buy” from the eight research firms that ...

Neurogene Inc. announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its NGN-401 Phase 1/2 trial for Rett syndrome. The company remains on ...

EDT Neurogene (NGNE) files $300M mixed securities shelfLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

In a report released today, Sami Corwin from William Blair reiterated a Buy rating on Neurogene ( NGNE – Research Report ). The company’s shares closed yesterday at $13.96.

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and ...